The new 7.2 mg dose is triple the previous highest dose of 2.4 mg

The issue: Average weight loss with the highest dose of Wegovy is 13% to 16%, while its main competitor, Zepbound, has a mean weight loss of 20% to 22% at its highest dose

Why this matters: A study comparing Wegovy doses of 2.4 mg and 7.2 mg found that the higher dose caused more weight loss, but also more gastrointestinal side effects and dysaesthesia.

Primary care relevance: Providers will soon be able to prescribe the higher dose, but should counsel patients about the potential for more gastrointestinal side effects and dysaesthesia.

First oral GLP-1 receptor agonist approved for weight loss

The issue: Patients who dislike injecting themselves now have an FDA-approved oral GLP-1 receptor agonist option for weight loss.

Primary care relevance: Providers now have an oral option for patients who prefer not to use injectable GLP-1 therapy for weight management.

The question now is what will insurance companies require to cover it

The issue: MASH (formerly NASH) is a leading cause of liver disease with limited approved treatments; GLP-1 agonists have shown benefit in trials.

Primary care relevance: Providers have a new pharmacologic option for MASH; access may depend on payer requirements for diagnosis and prior authorization.

Head-to-head trial found Zepbound superior to Wegovy for weight loss, with similar side effect profiles

The issue: Individual trials show that Zepbound causes more weight loss than Wegovy. A head-to-head trial would provide conclusive evidence.

Why this study matters: Compares Zepbound and Wegovy in a head-to-head trial.

Primary care relevance: Provides evidence on the benefits of Zepbound over Wegovy for weight loss.

Substantial weight loss with Wegovy led to reductions in pain and improved function

The issue: Obesity is a major risk factor for knee osteoarthritis; whether weight loss with GLP-1 agonists improves symptoms is unclear.

Why this study matters: Evaluates the effects of GLP-induced weight loss on knee osteoarthritis symptoms in obese patients.

Primary care relevance: Provides evidence on the benefits of GLP-1 agonist therapy for obesity in knee osteoarthritis.